9Nyman H,Adde M,Karjalainen-Lindsberg ML,et al.Prognostic impact of immunohistochemically defined germinal centre phenotype in diffuse large B-Cell lymphoma patients treated with immunochemotherapy[J].Blood,2007,109(11):4930-4935.
10Lisa B, Giulino MD, James B, et al. Treatment with rituximab in benign and malignant hematologic disorders in children[J]. The Journal of Pediatrics,2007,4:399-344.
3Tanimoto K, Kaneko A, Suzuki S, et al. Long-term foUow-up results of no initial therapy for ocular adnexal MALT lymphoma [ J ]. Ann Oncol, 2006, 17(1) : 135 -140.
4Tanimoto K, Kaneko A, Suzuki S, et al. Primary ocular adnexal MALT lymphoma: a long-term follow-up study of 114 patients[ J]. Jpn J Clin Oncol, 2007, 37(5) : 337 -344.
5Tran KH, Campbell BA, Fua T, et al. Efficacy of low dose radio-therapy for primary orbital marginal zone lymphoma [ J ]. Leuk Lym- phoma, 2013, 54(3) : 491 -496.
6Fasola CE, Jones JC, Huang DD, et al. Low-dose radiation therapy (2 Gy ~ 2) in the treatment of orbital lymphoma [ J ]. Int J Radiat Oncol Biol Phys, 2013, 86(5) : 930 -935.
8Johnston A, Bouafia-Sauvy F, Broussais-Guillaumot F, et al. Re- treatment with n'tuximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study[ J]. Leuk Lymphoma, 2010, 51 (3) :399 - 405.
9P~ate Y, Hemandez-Machin B, P6rez-M6ndez LI, et al. Intrale- sional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas : an epidemiologieal observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma[ J]. Br J Derma- tol, 2012, 167 ( 1 ) : 174 - 179.
10Savino G, Battendieri R, Balia L, et al. Evaluation of intraorbital injection of rituximab for treatment of primary ocular adnexal lym- phoma: a pilot study[J]. Cancer Sci, 2011, 102(8): 1565 - 1567.
